Exzeo Group, Inc. (XZO) Market Cap & Valuation Ratios
Exzeo Group, Inc. (XZO) has a market cap of $1.5B, a trailing P/E of 17.1 and a price-to-sales ratio of 6.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XZOExzeo Group, Inc.Follow XZO — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- 17.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
software - application · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| XZO | 1.5 | 17.1 | 6.3 | 12.6 | 6.4% | +22% | 49% | 53% |
| BTDR | 1.9 | — | 4.0 | 10.0 | — | +128% | 26% | 6% |
| ALKT | 1.7 | — | 4.1 | — | 3.2% | +27% | -7% | -5% |
| LIME | 1.7 | — | — | — | — | — | 4% | — |
| PDFS | 1.7 | 157.3 | 6.7 | 47.1 | -0.1% | +23% | 8% | 4% |
| EVCM | 1.6 | 48.6 | 3.4 | 16.3 | 4.4% | +4% | 10% | 5% |
| CXM | 1.6 | 66.9 | 1.5 | 20.3 | 7.1% | +6% | 5% | 10% |
| PD | 1.4 | — | 2.6 | 29.6 | 8.5% | +2% | 6% | 8% |
| DFIN | 1.4 | 38.3 | 2.0 | 7.5 | 11.2% | +3% | 19% | 18% |
| RDVT | 1.3 | 71.5 | 12.6 | 43.3 | 2.6% | +20% | 18% | 25% |
| GTM | 1.3 | — | 1.9 | — | — | +3% | -35% | -19% |
| Median of these 10 | 66.9 | 3.4 | 20.3 | 4.4% | +6% | 7% | 6% |
P/E 17.1 vs. a peer median of 66.9; EV/Sales 6.3 vs. 3.4.
Growth vs. price
each dot a company · hover or tap for valuesBTDR and ALKT and LIME and PD and GTM have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Exzeo Group, Inc. — questions
- What is Exzeo Group, Inc.'s market cap?
- $1.5B.
- What is Exzeo Group, Inc.'s P/E ratio?
- 17.1 on trailing twelve-month earnings to 2026-06-30.
- What is Exzeo Group, Inc.'s price-to-sales ratio?
- 6.9.
Every figure on this page comes from Exzeo Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.